What is the specific role of the cleavable linker in the anti-MIgG(Fc)-C-PNU ADC?

The cleavable linker in the anti-MIgG(Fc)-C-PNU ADC ensures that the cytotoxic agent, PNU-159682, remains attached to the antibody during circulation and is only released after the ADC has been internalized by the target cell. This targeted release mechanism reduces off-target effects and enhances the therapeutic efficacy by ensuring that the cytotoxic payload acts directly within the cancer cells.

How does PNU-159682 function within the anti-MIgG(Fc)-C-PNU ADC to induce cytotoxicity?

PNU-159682, a potent cytotoxic molecule in this ADC, binds to the DNA of cancer cells, causing severe DNA damage. This damage inhibits DNA replication and transcription, leading to cell death. PNU-159682's ability to bind DNA makes it highly effective in killing rapidly dividing cancer cells.

What advantages does the anti-MIgG(Fc)-C-PNU ADC offer for pre-screening mouse monoclonal antibodies?

The anti-MIgG(Fc)-C-PNU ADC allows researchers to evaluate the therapeutic potential of mouse monoclonal antibodies efficiently and economically. It targets cells that express mouse IgG Fc receptors, making it useful in identifying promising ADC candidates without the need for extensive preliminary testing.

Are there any known resistance mechanisms against the anti-MIgG(Fc)-C-PNU ADC in cancer treatment?

Resistance to ADCs like anti-MIgG(Fc)-C-PNU may arise due to changes in the expression levels of Fc receptors, modifications in the internalization pathways, or enhanced DNA repair mechanisms in target cells. Understanding these resistance mechanisms can guide the development of combination therapies to overcome them.

What experimental controls are recommended when using the anti-MIgG(Fc)-C-PNU ADC in laboratory studies?

For accurate and reliable results when using the anti-MIgG(Fc)-C-PNU ADC in experiments, it is crucial to include both positive and negative controls. A positive control should involve cells known to express mouse IgG Fc receptors to confirm the ADC's targeting and cytotoxic effects. Negative controls should include cells that do not express these receptors to assess non-specific toxicity and ensure the specificity of the ADC's action.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-MIgG(Fc)-C-PNU ADC

anti-MIgG(Fc)-C-PNU ADC (CAT#: ADC-AA-025)

This ADC product is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to PNU-159682. The antibody portion is a secondary antibody and the drug portion, PNU-159682, is a cytotoxic small molecule which binds to DNA, causes DNA damage. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
anti-mouse IgG Fc specific polyclonal IgG antibody

Species Reactivity
Mouse

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
PNU-159682

Description
PNU-159682 is a major bioactive metabolite of Nemorubicin in human liver microsomes;> 3,000-fold cytotoxic than its parent compound (MMDX and doxorubicin).

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-025. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Exceptional ADC Performance

The anti-MIgG(Fc)-C-PNU ADC from Creative Biolabs delivers targeted DNA damage with PNU-159682 efficiently, enhancing our cancer research protocols.

Excellent

Cost-Effective for Lab Use

Utilizing the anti-MIgG(Fc)-C-PNU ADC has significantly cut down our costs for pre-screening mouse monoclonal antibodies, without compromising on results.

Excellent

Reliable for Complex Studies

The specific targeting of IgG Fc regions and subsequent DNA damage caused by PNU-159682 makes this ADC a staple in our cytotoxicity research.

Excellent

Highly Recommended ADC

We've observed enhanced ADCC and reduced opsonization in our experiments, making it an essential asset for studying immune responses.

Excellent

Top-Notch Precision

Creative Biolabs' anti-MIgG(Fc)-C-PNU ADC provides consistent and reliable results in inducing DNA damage, crucial for our therapeutic studies.

Excellent

Innovative and Effective

This ADC combines excellent targeting with potent cytotoxic effects, streamlining our research on antibody-mediated cell regulation.

Q: 1: What is the specific role of the cleavable linker in the anti-MIgG(Fc)-C-PNU ADC?
A: The cleavable linker in the anti-MIgG(Fc)-C-PNU ADC ensures that the cytotoxic agent, PNU-159682, remains attached to the antibody during circulation and is only released after the ADC has been internalized by the target cell. This targeted release mechanism reduces off-target effects and enhances the therapeutic efficacy by ensuring that the cytotoxic payload acts directly within the cancer cells.
Q: 2: How does PNU-159682 function within the anti-MIgG(Fc)-C-PNU ADC to induce cytotoxicity?
A: PNU-159682, a potent cytotoxic molecule in this ADC, binds to the DNA of cancer cells, causing severe DNA damage. This damage inhibits DNA replication and transcription, leading to cell death. PNU-159682's ability to bind DNA makes it highly effective in killing rapidly dividing cancer cells.
Q: 3: What advantages does the anti-MIgG(Fc)-C-PNU ADC offer for pre-screening mouse monoclonal antibodies?
A: The anti-MIgG(Fc)-C-PNU ADC allows researchers to evaluate the therapeutic potential of mouse monoclonal antibodies efficiently and economically. It targets cells that express mouse IgG Fc receptors, making it useful in identifying promising ADC candidates without the need for extensive preliminary testing.
Q: 4: Are there any known resistance mechanisms against the anti-MIgG(Fc)-C-PNU ADC in cancer treatment?
A: Resistance to ADCs like anti-MIgG(Fc)-C-PNU may arise due to changes in the expression levels of Fc receptors, modifications in the internalization pathways, or enhanced DNA repair mechanisms in target cells. Understanding these resistance mechanisms can guide the development of combination therapies to overcome them.
Q: 5: What experimental controls are recommended when using the anti-MIgG(Fc)-C-PNU ADC in laboratory studies?
A: For accurate and reliable results when using the anti-MIgG(Fc)-C-PNU ADC in experiments, it is crucial to include both positive and negative controls. A positive control should involve cells known to express mouse IgG Fc receptors to confirm the ADC's targeting and cytotoxic effects. Negative controls should include cells that do not express these receptors to assess non-specific toxicity and ensure the specificity of the ADC's action.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-055	Protein A-Duocarmycin ADC		Duocarmycins
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-062	Anti-HIgG(Fc)Fab-C-DX8951 ADC	Cleavable linkers	DX8953
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-017	anti-HIgG(Fab)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-011	anti-HIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-014	anti-HIgG(Fc)Fab-C-PNU ADC	Cleavable linkers	PNU-159682
ADC-AA-007	anti-HIgG(Fc)-C-PNU ADC	Cleavable linkers	PNU-159682

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.